When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan

BACKGROUND: The addition of anti-angiogenesis drugs to epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI) or chemotherapy in patients with EGFR-mutant non–small cell lung cancer (NSCLC) can improve disease control. We conducted a study to evaluate the efficacy of combination the...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Chieh-Lung, Wang, Sing-Ting, Liao, Wei-Chih, Chen, Chia-Hung, Tu, Chih-Yen, Chen, Hung-Jen, Hsia, Te-Chun, Cheng, Wen-Chien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125911/
https://www.ncbi.nlm.nih.gov/pubmed/35599308
http://dx.doi.org/10.1186/s12885-022-09672-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9125911/
https://www.ncbi.nlm.nih.gov/pubmed/35599308
http://dx.doi.org/10.1186/s12885-022-09672-4

Ejemplares similares